Global Rna Targeting Small Molecule Drug Discovery Market Scope 2024, Forecast To 2033
8 Mar, 2024
The RNA targeting small molecule drug discovery market has seen exponential growth, rising from $1.45 billion in 2023 to $1.78 billion in 2024, with a CAGR of 22.3%, driven by genomic discoveries and therapeutic advancements. Future growth is expected, reaching $3.97 billion by 2028, with a CAGR of 22.2%, propelled by RNA epigenetics and AI integration. Trends include RNA editing and CRISPR technologies.
Global RNA Targeting Small Molecule Drug Discovery Market Key Driver
The rising sale of luxury cars contributes to the growth of the high-performance wheel market. Luxury car sales increased from 5,586 to 6,021 in 2022, indicating a rising demand for high-performance wheels to enhance driving experience and safety.
Get A Free Sample Of The Global RNA Targeting Small Molecule Drug Discovery Market ReportGlobal RNA Targeting Small Molecule Drug Discovery Market Segments
The rna targeting small molecule drug discovery market covered in this report is segmented –
1) Target RNA Type:Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)
2) Technology:CRISPR-Cas9, RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies
3) Therapeutic Area:Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas
4) Delivery Method:Intravenous (IV), Oral, Topical, Other Methods
5) Application:Research Use, Therapeutic Use, Diagnostic Use, Other Applications
By Geography: The countries covered in the rna targeting small molecule drug discovery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
North America was the largest region in the RNA targeting small molecule drug discovery market in 2023. The regions covered in the rna targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major RNA Targeting Small Molecule Drug Discovery Industry Players
F. Hoffmann-La Roche Ltd ; Merck & Co. Inc; Bayer AG; Novartis AG; Sanofi SA; Bristol-Myers Squibb Company; AstraZeneca PLC; Takeda Pharmaceutical Company Limited; Eli Lilly and Company; Amgen Inc.; Novo Nordisk Inc.; Moderna Inc.; Astellas Pharma Inc.; Biogen Inc.; Alnylam Pharmaceuticals Inc.; Sarepta Therapeutics Inc.; Evotec A.G.; PTC Therapeutics Inc.; Ionis Pharmaceuticals Inc.; Dicerna Pharmaceuticals Inc.; Arrakis Therapeutics; Arbutus Biopharma Corporation; H3 Biomedicine Inc.; Anima Biotech Inc.; Ribometrix Inc.; Quark Pharmaceuticals Inc.; Regulus Therapeutics Inc.; Skyhawk Therapeutics Inc.; Accent Therapeutics Inc.; Epics Therapeutics; Expansion Therapeutics
Get The Full Global RNA Targeting Small Molecule Drug Discovery Market Report
RNA Targeting Small Molecule Drug Discovery Market Overview
RNA targeting small-molecule drug discovery refers to identifying and developing small-molecule drugs that interact with RNA molecules to modulate their function or activity. This process is used for discovering innovative medicines that would be used for treating various diseases, including genetic disorders, viral infections, neurodegenerative diseases, and cancer.